Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

The article favors AbbVie over Pfizer for dividend investors despite Pfizer's higher 6.1% yield, citing AbbVie's 53-year dividend-growth record, 5.5% 2026 dividend increase to $1.73 per quarter, and lower 65% FCF payout ratio versus Pfizer's roughly 89%. AbbVie reported Q2 sales of $16.9 billion, up 10.2% year over year, while EPS rose 290% to $2.03; Skyrizi and Rinvoq generated $5.5 billion and $2.52 billion, respectively, helping offset Humira's decline. Pfizer faces an estimated $17 billion-$18 billion annual revenue exposure from patent expirations during 2026-2028, creating greater pressure on cash flow, leverage, and dividend sustainability.

Analysis

The investable distinction is not dividend yield but the durability of cash conversion after patent erosion. ABBV's immunology franchise is now concentrated in two large assets, creating a new single-franchise risk: a meaningful safety signal, slower-than-expected label expansion, or payer step-editing could simultaneously pressure growth, the earnings multiple, and dividend coverage. Conversely, PFE's depressed valuation likely already discounts substantial erosion, so incremental upside depends less on legacy products and more on whether its oncology pipeline and acquired ADC platform convert into visible revenue before the 2026-28 loss-of-exclusivity drag peaks.

Near term (1-3 months), this is primarily an earnings-estimate and capital-allocation trade rather than a dividend trade. ABBV can sustain a premium only if immunology growth continues to offset Humira decay while acquired oncology assets demonstrate accretion; leverage makes further large M&A less attractive if rates or credit spreads widen. PFE's high payout is a warning signal rather than a catalyst: absent pipeline beats, management may have to prioritize deleveraging and business-development spending over dividend growth, limiting the usual defensive-healthcare bid.

The contrarian view is that ABBV may be the consensus quality long while PFE is the more asymmetric recovery candidate. If Seagen-derived oncology revenues inflect and the obesity pipeline gains credible differentiation, PFE can rerate from a patent-cliff multiple despite declining legacy sales; this requires evidence in quarterly guidance, not just pipeline narratives. The article's cited acquisition claims and financial comparisons should be independently verified before underwriting either balance-sheet conclusion, particularly the status, price, and financing of any APGE-related transaction.

Key Decisions for Investors

• Maintain a 6-12 month quality pair: long ABBV / short PFE in equal beta-adjusted dollars. The thesis is relative estimate resilience and superior capital-return flexibility; cut or reduce if ABBV immunology growth falls below management's replacement trajectory or PFE raises forward revenue/earnings guidance on oncology execution.
• Do not chase ABBV solely for income. Add only following an earnings-driven pullback that is not accompanied by weaker Skyrizi/Rinvoq prescription trends; the principal downside is concentrated immunology exposure plus M&A/leverage concerns, not near-term Humira comparisons.
• Place a 1-3 month PFE catalyst watch around quarterly oncology revenue, Seagen synergy disclosure, and 2027 cash-flow/dividend commentary. Consider a tactical long only if management demonstrates that new-product growth can narrow the LOE gap; otherwise the yield offers insufficient protection against another estimate reset.
• For a sector hedge, own ABBV against an equal-dollar short in a diversified large-pharma proxy such as PFE rather than broad XLV: broad healthcare exposure introduces managed-care, provider, and GLP-1 variables unrelated to the patent-cliff thesis.